Trials / Completed
CompletedNCT02045212
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Regenera Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the treatment phase to another 13 weeks (26 weeks total), and at the follow-up visit at 3 month after end of treatment in patients with optic nerve neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPh201 | SC injection twice a week during 13/26 weeks |
| DRUG | Placebo | SC injection twice a week during 13/26 weeks |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-08-01
- Completion
- 2016-12-01
- First posted
- 2014-01-24
- Last updated
- 2020-03-19
- Results posted
- 2019-03-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02045212. Inclusion in this directory is not an endorsement.